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The first patient with Wilms' Tumour to be entered onto the Children's
Cancer Registry at the Red Cross Children's Hospital was a 19-month-old
girl. She was admitted in December 1966 with a left-sided Wilms' tumour.
She was given dactinomycin and radiotherapy pre-operatively and then
came to nephrectomy, after which she received further radiotherapy. She
relapsed with a pulmonary metastasis three years later. This was removed
at thoracotomy and she was treated by Cyril Karabus with vincristine and
dactinomycin for the next 18 months. When she was lost to follow up nine
years later in 1980, she remained alive and disease free. Three hundred and
twenty six patients with Wilms' Tumour have followed in her footsteps. Most
of them are also survivors.
This thesis should stand as a tribute to Cyril Karabus and his successors,
Paddy Hartley and Farieda Desai, who have delivered quality care to several
generations of children suffering from both malignancies and haematological
disorders.
While modern multimodal cancer therapy has yielded results of which we
can be rightfully proud, it remains an ongoing responsibility to audit those
outcomes. Where we fall short of the high standards set by international
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BWT Bilateral Wilms' Tumour
BWS Beckwith-Wiedemann syndrome
CT Computed Tomography
EFS Event Free Survival
FH Favourable Histology
GPOH German Society for Paediatric Haematology and Oncology
Gy Gray (a unit of measure of absorbed radiation dose)
IE Ifosfamide and Etoposide
ICE Ifosfamide, Carboplatin and Etoposide
IVCT Inferior vena cava tumour thrombosis
NWTS National Wilms' Tumor Study
NWTSG National Wilms' Tumor Study Group
OS Overall Survival
PTT Partial Thromboplastin Time
RCCH Red Cross Children's Hospital
RFS Relapse Free Survival
SIOP International Society of Paediatric Oncology
UFH Unfavourable Histology
UKCCSG United Kingdom Children's Cancer Study Group
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In Africa Wilms' tumour frequently presents with advanced disease. This
study reports our results over 25 years using the National Wilms' Tumor
Study Group approach of primary surgery, in the form of nephrectomy,
followed by chemotherapy. A small number of these tumours are bilateral
and here surgery has evolved from simple nephrectomy into the use of
nephron-sparing techniques.
METHODS
A retrospective analysis was performed on all patients diagnosed with
Wilms' tumour between January 1979 and December 2003. Treatment was
according to National Wilms' Tumor Study Group protocols. For unilateral
Wilms' tumour primary surgery, where possible, was followed by adjuvant
chemotherapy with vincristine and dactinomycin. Doxorubicin was added for
stage III and IV tumours. Other drugs were used for unfavourable histology,
and radiotherapy was reserved for local stage III tumours and pulmonary
metastases. Patients with bilateral Wilms' tumours underwent initial
bilateral biopsy, neoadjuvant chemotherapy and tumourectomy. Where
indicated, nephrectomy (partial or complete) involved using ice dam topical
cooling and vascular control, and in one case bench surgery and extensive
renal reconstruction with orthotopic autotransplantation. Revision











nephroblastomatosis. Radiotherapy was reserved for pulmonary metastases
and palliation.
RESULTS
There were 188 children with unilateral Wilms' tumour and 20 with bilateral
Wilms' tumour. Among those with unilateral Wilms' tumour fifty seven
(30.3%) were stage I, 33 (17.6%) were stage II, 60 (31.9%) were stage III and
38 (20.2%) were stage IV. Twenty-four patients (12.8%) had unfavourable
histology. Fifteen of the bilateral Wilms' tumours had a synchronous
presentation, one with liver metastases at diagnosis, and five were
metachronous. Nephroblastomatosis was identified in 18 of the 20 patients
(90%) with bilateral Wilms' tumour.
One hundred and forty five patients are alive and disease free, 23 to 318
months from diagnosis. The estimated 5-year overall survival for all
unilateral Wilms' tumours was 78.3%; 82.8% for favourable histology and
47.3% for unfavourable histology. Among those with favourable histology,
estimated 5-year overall survival was 94.6% for stage I, 96.2% for stage II,
78.4% for stage III and 54.2% for stage IV. There was no difference in overall
survival between those favourable histology stage III tumours that were
operable and those deemed inoperable. Intra-operative spillage was
uncommon (8%), and did not increase local relapse rate. Survival of stage IV











Among those with bilateral Wilms' tumours, 11 are alive free of disease one
to fifteen years after completing treatment, all with well-preserved renal
function. Nine have died (two of unrelated disease), including six of the
seven with spread outside the kidney. All three with unfavourable histology
are alive, as are four of the five with a metachronous presentation. Survival
for bilateral Wilms' tumour has improved markedly in the last decade.
CONCLUSIONS AND RECOMMENDATIONS
National Wilms' Tumor Study Group protocols employed in a South African
setting with highly competent and experienced surgical care, produced
results for non-metastatic favourable histology unilateral Wilms' tumour
comparable to those of the National Wilms' Tumor Study Group. For
bilateral Wilms' tumours appropriate chemotherapy together with
conservative (nephron-sparing) and innovative surgery produced good results
with preservation of adequate renal function in nearly all cases.
We can seek to improve outcomes via better risk stratification with
molecular markers, new adjuvant chemotherapy regimes for high risk
tumours and novel surgical approaches to improve nephron-sparing in
bilateral Wilms' tumour. Improving results in Stage IV patients may depend
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Wilms' tumour (WT) or nephrobastoma is one of the paediatric embryonal
tumours. It was named for Max Wilms, a German surgeon of the nineteenth
century who wrote a monograph on the subject in 1899. 1 The tumour arises
from the primitive kidney or metanephric blastema and in its classic form
consists of three elements; blastema, stroma and an epithelial component.
WT is the most common childhood renal tumour. In North America it is the
fourth commonest malignancy among children under the age of fifteen. 2
Only acute lymphoblastic leukaemia, brain tumours and neuroblastomas
occur more frequently [figure 1]. The annual incidence of WT in the United
States among children under fifteen between 1975 and 1995 was 7.6 per
million. 3
WT has been found to be slightly more common among blacks than whites.
Annual incidence per million 0-19 year olds in the United States between
1990 and 2001 was 7.6 for blacks and 6.9 for whites. For neuroblastoma the
annual incidence per million was 7.4 for blacks and 9.1 for whites. 2
Accurate population-based figures for South Africa are not available. Figures
from the South African Children's Cancer Study Group reveal that WT is the












Distribution of specific cancer diagnoses for children (0 to 14
years) and adolescents (15 to 19 years), 1992 to 2001.
Percent distribution by International Classification of Childhood Cancer diagnostic groups
and subgroups for younger than 15 years and 15 - 19 years of age (all races and both sexes).
ALL = acute lymphoblastic leukaemia; RMS = rhabdomyosarcoma; STS = soft tissue sarcoma.
(Incidence data are from the Surveillance, Epidemiology, and End Results program, National
Cancer Institute).
Reference: Gurney JG, Bondy ML. Epidemiology of Childhood Cancer. In: Pizzo PA, Poplack
DG, eds. Principles and Practice of Pediatric Oncology, 5 th ed. Philadelphia: Lippincott











Wessels). Using data from STATS SA Census 2001 4 we can estimate that the
annual incidence per million among 0 to 14-year-olds in the Western Cape is
7.3 for WT and 4.6 for neuroblastoma.
Mean age at diagnosis is approximately 3.5 years for unilateral WT (UWT),
with a median of 35 months for boys and 42 months for girls. 5 Bilateral
Wilms' tumour (BWT) typically occurs at a younger age, 6 with a median of
23 months for boys and 28.5 months for girls. There is a slight female
preponderance with a male:female ratio of 0.92:1 for UWT and 0.6:1 for
BWT. 5
About 10% of children with UWT 7 and 20-28% of those with BWT8,9,10 have
recognised malformations. These may be isolated urogenital abnormalities
such as cryptorchidism, hypospadias, double collecting system and
horseshoe kidney, 11 or recognizable phenotypic syndromes. These
syndromes can be divided into those characterised by overgrowth such as
Beckwith-Wiedemann syndrome (BWS), 1 2 isolated hemihypertrophy or
Perlman syndrome, and those not associated with overgrowth such as
aniridia, WAGR syndrome (WT, aniridia, ambiguous genitalia, and mental
retardation) 13 ' 14 and Denys-Drash syndrome (WT, ambiguous genitalia and
mesangial sclerosis with proteinuria). 15 These syndromes have in common
abnormalities of the short arm of chromosome 11 (11p) involving either the
WT1 gene (aniridia or Denys-Drash syndrome) 16 or the WT2 gene (BWS). WT1
mutations are also found in 2% of phenotypically normal children with WT. 17











gonadal development. It acts as a tumour suppressor gene by decreasing the
expression of growth associated genes such as Insulin-like growth factor 2. 18
WT2 encodes a growth factor, probably Insulin-like growth factor 2, whose
increased expression results in BWS and WT.
Additional tumour suppressor genes have been identified on the long arm of
chromosome 16 (16q) and the short arm of chromosome 1 (1p). Loss of
heterozygosity at these loci occurs in association with some cases of WT,
and confers an adverse prognosis. 19 Mutations of the p53 tumour suppressor
gene also carry a poor prognosis, 20 although there is some dispute as to
whether they cluster with advanced stage or anaplastic histology.
18
Recently, overexpression of genes on the long arm of chromosome 1 (1q)
was also identified as a potential marker for poor prognosis and relapse. 21
Despite the number of genes involved in the development of WT, hereditary
WT is uncommon, with only 1% to 2% of patients having a positive family
history. 18 Affected family members are usually siblings or cousins. BWT is
seldom familial, though one pair of sisters was described in 1967. 22
WT arises in the kidney and metastasizes by way of vascular invasion to the
liver, the lungs, and rarely the central nervous system. Stage I tumours are
confined within the capsule of the kidney, Stage II tumours have penetrated
the capsule but without local spread outside the kidney and Stage III
tumours have local extrarenal spread (this includes extension into the











designated Stage IV. Most patients in the developed world are low stage at
diagnosis. The third National Wilms' Tumour Study Group trial (NWTS-3)
reported a stage distribution as follows: stage I 47%, stage II 21%, stage III
21% and stage IV 11%. 23 Advanced stage carries a poor prognosis. Four-year
OS for stages I through IV reported by the fourth National Wilms' Tumour
Study Group trial (NWTS-4) were 95.6%, 91.1%, 90.9%, and 80.9%
respectively. 24
Synchronous BWT represent 4-7% of all WT, 25 and are designated stage V.
They usually present at a younger age than UWT; 6 age over three years at
diagnosis carries a poor prognosis. 26 About 1% of UWT go on to develop
contralateral disease or metachronous BWT. More than 95% of these second
tumours develop within five years. 27 The risk is increased in children under
the age of 12 months with nephrogenic rests at diagnosis. 28
Nephrogenic rests are persistent clusters of embryonal cells representing
microscopic malformations of the developing kidney. 29 They are found in
about 1% of infant autopsies and are usually absent by the age of four
months.30 They may be intralobar, which are frequently associated with
mutations or deletions of WT1, or perilobar, which typically occur in the
overgrowth syndromes. Incipient or dormant rests may regress or become
sclerotic. Alternatively, they may become hyperplastic, some going on to
become neoplastic and develop WT. 31 Nephrogenic rests are seen in 90% of











with synchronous BWT in NWTS series have multiple nephrogenic rests or
nephroblastomatosis."
Apart from clinical stage, prognosis is most influenced by histology.
Favourable histology (FH) tumours consist of one or more of the three
components that make up the typical triphasic histology. These are
epithelial elements, blastema or stroma. Blastema rich tumours tend to be
invasive but often respond well to chemotherapy, 33 whereas epithelial rich
tumours and the rhabdomyomatous variant (where the tumour cells
resemble muscle cells) are usually less aggressive but respond less well to
chemotherapy. 34 ' 35 ' 36 Unfavourable histology (UFH) is designated anaplastic.
Anaplasia is defined by the presence of enlarged polyploid nuclei with
hyperchromasia and a high mitotic index within the tumour sample. It
occurs in about 5% of UWT and about 10-15% of BWT, more commonly in
older than younger children. 37 Anaplasia may be focal or diffuse, the latter
being recognised as much more adverse. 38 ' 39 Nuclear unrest, characterized
by an increase in nuclear size without an increase in mitoses, is not
associated with a worse outcome than FH. 4°
A number of paraneoplastic syndromes have been associated with WT. 41 The
most common is hypertension due to tumour production of renin. This is
seen in up to 25% of WT, 25 and may be sufficiently severe to cause
cardiomyopathy. 42 There have been a few reports of polycythaemia due to
elevated erythropoietin, 43 Cushing's syndrome due to ectopic ACTH 44 and











overproduction. 45 ' 46 Acquired von Willebrand disease has also been
described, 47 and is thought to be due to tumour production of antibodies to
the von Willebrand factor. Tumours that produce these paraneoplastic
effects are typically well-differentiated (FH) 48 and may be of low stage.
The first successful nephrectomy for WT was performed by Thomas Jessop in
1877 on a two-year-old boy at the Leeds General Infirmary. 49 Until the 1950s
management was surgical with cure only a possibility for local tumours. The
addition of adjuvant therapy in the form of chemotherapy and radiotherapy
has introduced the possibility of cure for metastatic WT, and greatly
improved the prognosis for non-metastatic disease. The use of dactinomycin
was pioneered by Sidney Farber50 in Boston during the mid-1950s, and
vincristine, 51 ' 52 doxorubicin 53 and cyclophosphamide were introduced during
the years that followed. Radiotherapy was used for the first time in 1916, 54
but only became routine postoperative treatment at the Boston's Children's
Hospital 55 during the 1940s. The development of treatment protocols
eventually led to the formation of large multicentre trials under the
auspices of the International Society of Paediatric Oncology (STOP) and the
National Wilms' Tumor Study Group (NWTSG). 56 ' 57
The five studies of the NWTSG were conducted between 1969 and 2002. The
central philosophy of the NWTSG is that all operable tumours should be
treated primarily with total nephrectomy before adjuvant treatment in the
form of radiotherapy and chemotherapy. The major findings of each trial 58











maximising survival while minimising toxicity. The first study of the NWTSG
(NWTS-1, 1969-1973) 59 demonstrated that stage I patients could be treated
without renal bed radiotherapy, and that stage II and III patients fared
better with the combination of vincristine and dactinomycin compared to
either drug alone. The second study (NWTS-2, 1974-1978) 53 demonstrated
that six months of vincristine and dactinomycin was as effective as 15
months of therapy for stage I tumours, and that the addition of doxorubicin
improved the relapse-free survival for stage II to IV tumours. The third study
of the NWTSG (NWTS-3, 1979-1986) 23 showed that FH stage I tumours could
be successfully treated with a 10-week regimen of vincristine and
dactinomycin without radiotherapy. Patients with stage II FH WT treated
with vincristine and dactinomycin achieved similar results as those who also
received doxorubicin or renal bed radiotherapy. Patients with stage III FH
tumours were given vincristine and dactinomycin with or without
doxorubicin, and were also randomised to 10 or 20 Gray (Gy) of
radiotherapy. Similar results were achieved for those who received
doxorubicin and 10 Gy as those who received 20 Gy alone, but there were
more relapses in the group who received 10 Gy alone. Long term follow up,
however, indicates no difference in overall survival (OS) between those
receiving doxorubicin and 10 Gy of radiotherapy and those receiving 10 Gy
alone. Thus, the use of doxorubicin for stage III FH WT is associated with
decreased relapse but there is no conclusive evidence that it improves
survival. 60 Patients with stage IV FH WT received renal bed radiotherapy and
12 Gy of whole lung irradiation, and were randomised to vincristine,











addition of cyclophosphamide did not confer a survival advantage over the
three-drug regime.
The fourth study of the NWTSG (NWTS-4, 1986-1993) compared "pulse-
intensive" regimens using single doses of dactinomycin and doxorubicin to
the traditional regimens using divided doses, and studied a reduction in
treatment duration from 15 to six months for stage II to IV FH tumours. 61
There was no significant difference in outcome for either of these
randomisations and cost analysis 62 showed a massive saving using the shorter
"pulse-intensive" regimens. The fifth study (NWTS-5, 1995-2002) utilized
regimens whose efficacy had been established by its predecessors and
preliminary results suggest that it now provides a reasonable standard of
care for the treatment of patients with FH WT. 25 Its primary goal was the
identification of biologic prognostic markers for FH WT such as loss of
heterozygosity at chromosomes 1p and 16q 19 and telomerase expression. 63 A
second objective was to examine the use of surgery only for stage I FH WT
weighing less than 550 grams in patients under the age of two years. This
randomisation was terminated early based on predefined stopping rules
because of an excess number of relapses in the trial arm, but all the
patients who relapsed were salvaged. Consequently observation without
chemotherapy remains a treatment consideration for this group of












As a result of these efforts current OS rates approach 90%. 6 The fourth
study of the NWTSG (NWTS-4) reported four-year OS for Stage I through IV of
95.6%, 91.1%, 90.9% and 80.9% respectively. 24 However the 4-year OS for
diffusely anaplastic tumours (stage II to IV) was only 52.2% in NWTS-3 and
NWTS-4. 65 This is in spite of the fact that treatment was intensified with
renal bed radiotherapy and doxorubicin, as well as cyclophosphamide and
etoposide.
STOP protocols utilise neoadjuvant chemotherapy followed by surgery.
66,67
The histology of the resected specimen then helps to dictate further
chemotherapy and radiotherapy.
68,69,70
Advocates argue that this limits
surgical complications by shrinking tumours (which may be of particular
importance with advanced disease in developing world settings)'and allows
for stratification based on tumour response to chemotherapy. This in turn
minimises the number of children requiring intensive treatment in the form
of cardiotoxic anthracyclines or renal bed irradiation. 72 ' 73 Architects of
NWTSG protocols 74 argue that the optimal approach is primary surgery,
which allows accurate assessment of original stage and histology, with
appropriate stratification of treatment. In early NWTS trials inoperable
tumours were staged by imaging and treated accordingly, but this group
fared poorly and subsequent trials treated all inoperable tumours with Stage
III protocols. 75 STOP protagonists suggested that this might lead to over
treatment and the second United Kingdom Children's Cancer Study Group
(UKCCSG) WT Trial (UKW2) provided some data to support this. 76 In this trial











least some of them must have been Stage II. The only randomised trial to
directly compare pre-operative chemotherapy and primary surgery was the
third UKCCSG WT Trial (UKW3). 77 The investigators experienced
considerable difficulty accruing patients for this randomisation. They found
a lower proportion of Stage III tumours and less tumour spill or rupture in
the pre-operative chemotherapy cohort. There was no significant difference
in the relapse rate or survival between the cohorts.
There are few reported series of WT from Africa. Hadley et a1 78 reported on
78 black South African children from KwaZulu-Natal with WT. They noted a
high proportion of advanced local and metastatic disease (53% were stages
III and IV) as well as generally poor outcomes. In addition, treatment was
compromised by a high incidence of nutritional and infective co-morbidity.
Of the 78 children, eight declined treatment or absconded and 16 died
during or prior to pre-operative chemotherapy. Only 54 (69%) came to
nephrectomy, 31 primarily and 23 after chemotherapy with or without
radiotherapy. Long-term survival of this cohort was not reported. A more
recent study by the same group" reported a 63% OS for a cohort of 67
patients with large tumours (all resected specimens weighed more than one
kilogram). This group, like many others in Africa" and other parts of the
developing world, utilised protocols based on the STOP approach. This
strategy is aimed at facilitating surgery in the setting of advanced disease,











Zhaghloul et a1 81 confirmed a high proportion of advanced disease (51% were
stages III and IV) in a series of 112 children in Egypt. Using NWTSG-based
protocols, with primary surgery followed by chemotherapy, they reported
good results for non-metastatic tumours (10 year actuarial survival of 94%
for stage I, 86% for stage II and 71% for stage III).
Ekenze et al 82 also utilised primary surgery followed by chemotherapy for 42
Nigerian children, 83.3% of whom had stage III or IV disease. There was a
high rate of abandonment (in part because families are unable to afford the
chemotherapy which is self-funded) and a high rate of relapse. OS was only
40%.
We have also utilised a NWTSG-based approach for UWT for many years.
Tumours deemed operable, even in the face of pulmonary metastases, were
resected prior to the initiation of chemotherapy. Where the surgeons felt
that the tumour could not be resected safely, neoadjuvant chemotherapy
was administered and the patient reviewed at four to six weeks with a view
to surgery. The current WT protocol employed by the Red Cross Children's
Hospital (RCCH) Oncology Service is designated 5981 and is based on NWTS-5
protocols. See Appendix 2.
There are some advocates of partial nephrectomy instead of total
nephrectomy for favourable risk UWT. 83 ' 84 ' 85 Partial nephrectomy was used
off protocol for 37 UWT patients in SIOP93-01 /GPOH. 86 These patients had a











nephrectomy. Nonetheless, total nephrectomy with palpation of the
contralateral kidney to exclude bilateral disease 87 remains the mainstay of
treatment. Beckwith-Wiedemann syndrome 88 is an exception to this rule
since these patients are at risk of both metachronous tumours and non-
malignant renal disease. Renal anomalies such as horseshoe and single
kidney also mandate partial nephrectomy, and it should be considered
where contralateral nephroblastomatosis is established on imaging prior to
surgery.
Radiotherapy for WT has two principal applications - to the renal bed
following surgery and for pulmonary metastases - and has also been used for
metastases or relapsed disease in the liver or central nervous system.
Renal bed radiotherapy is utilised for locally advanced tumours. Radiation
dose has diminished from 18 - 40 Gy based on age in the 19705 58 to 10.8 Gy
on NWTS-5. Where there has been pre-operative rupture or peri-operative
spill beyond the flank, irradiation of the whole abdomen is advocated. 89
Approaches to lung metastases vary. The NTWSG advocates that pulmonary
metastases visible on chest xray should be treated with whole lung
irradiation. FH WT with pulmonary lesions identified on computed
tomography (CT) scan only on NWTS-3 and NWTS-4 were treated either as
stage IV tumours or by local stage at the investigator's discretion. 9° Event
free survival (EFS) for the 53 treated with three drugs (vincristine,
dactinomycin and doxorubicin) and pulmonary radiotherapy was 89%











The difference was not statistically significant but the study was
underpowered because the sample size was too small. Those treated with
pulmonary radiotherapy had fewer pulmonary relapses but more deaths
attributable to lung toxicity.
Considering FH stage IV patients treated on NWTS-4 and NWTS-5, 231 had
pulmonary metastases on chest xray and 186 had pulmonary lesions on CT
scan only. 91 There was an inferior relapse free survival (RFS) for those
treated with vincristine and dactinomycin compared to those who also
received doxorubicin, regardless of whether they received pulmonary
radiotherapy or not. This suggests that small lesions require more intensive
chemotherapy than that used for low stage tumours, but perhaps less
treatment than for traditional metastatic disease. The current
recommendation is that lesions identified on CT scan only do not
automatically receive radiotherapy but should be biopsied with a view to
intensifying therapy if they do not resolve after six to eight weeks of
chemotherapy. Future NWTS trials will likely abandon chest xray
appearance as a way of stratifying pulmonary metastases. 92 All pulmonary
metastases visible on CT scan will be treated with three-drug
chemotherapy, reserving radiotherapy for non-responders with biopsy-
proven tumour deposits.
The major clinical challenge in BWT is the preservation of functioning renal
tissue while achieving cure with the minimum of therapy-related











presentation and advanced local disease, when there is a poor response to
chemotherapy or when a nephrectomy has already been done as in
metachronous presentation. In addition, management is frequently
complicated by the presence of multiple nephrogenic rests or
nephroblastomatosis. Even on biopsy, hyperplastic rests are difficult to
distinguish from and may transform into WT. 31 ' 97 Fortunately,
nephroblastomatosis is easy to follow up on serial imaging and does respond
to chemotherapy.
Early work clearly demonstrated that biopsy followed by neoadjuvant
chemotherapy was superior to surgical reduction at diagnosis. 98 It then
became increasingly clear that the first procedure after neoadjuvant
chemotherapy should be partial rather than total nephrectomy. The use of
partial nephrectomy or tumourectomy for BWT in NWTS-4 9 was associated
with a local recurrence rate of only 8.2%; 16% if the margins were
histologically positive and 6.3% if they were negative. Seventy two percent
of these kidneys were salvaged. A more recent report advocated an
extremely conservative approach: macroscopic tumour was resected with no
attempt to obtain clear microscopic margins in a series of 14 cases of
BWT. 99 Renal salvage techniques included the use of longitudinal incisions
with reconstruction of the renal pelvis. Thirteen of the fourteen are alive
and disease free with no patients in chronic renal failure; the sole death











While emphasis is increasingly placed on nephron-sparing surgical
approaches, it should be remembered that most deaths occur as a result of
progressive disease, and usually in the first two years after diagnosis. 25 Cure
rates of 70-80% have been reported for BWT;  ,8 9,100,101,102the 4-year OS for
stage V tumours in NWTS-5 was 81.7%. 61 For synchronous BWT, outcome is
influenced by local stage with stage I and II tumours faring better than those
that are stage 111. 103 Results for metachronous BWT have been reported as
inferior 103 or comparable100 to synchronous BWT. There appears to be a
better outcome if the time to development of the second tumour is less
than 18 months. 27
Long-term complications seen in WT survivors include renal impairment,
cardiomyopathy and second malignancies. Renal impairment typically
presents with proteinuria and / or hypertension culminating in renal failure
in 0.25% to 0.6% of UWT and between 3.8% and 11.5% of BWT. 01 4,105 Renal
failure develops in 50-74% of cases with Denys-Drash syndrome, usually
within five years. Appropriate management of these children entails
bilateral nephrectomy, with transplantation being offered after a disease
free interval of one to two years. 106 By contrast the patients with WAGR
syndrome and those with isolated genitourinary abnormalities, usually
present late with renal failure.14,105 Survivors of UWT should be closely
followed up with serial blood pressure and urinalysis but they can be
reassured about the risk of renal failure. In a study of forty WT patients who
were followed up for a mean of 8.8 years, two had proteinuria, but all had











Twenty five percent of WT patients treated with doxorubicin develop some
form of cardiac abnormality on echocardiogram. 108 The incidence of cardiac
failure for WT patients treated on NWTS protocols was 1.7% over the fifteen
years from diagnosis, 109 50% occurring within 8 years. The risk is increased
from 1% to 5.4% for those who also received pulmonary radiotherapy.
Fifteen years after WT diagnosis, the cumulative incidence of second
malignancy was 1.6% in a large series of patients treated on NWTS
protocols.110 There were 43 second malignancies, including 9 leukaemias, 4
lymphomas, 3 brain tumours and 13 sarcomas. This was somewhat lower on
SIOP studies, where a cumulative incidence of 0.65% was reported. 111 There
was consensus that the use of radiotherapy and anthracyclines place these
patients at greater risk of second malignancy.
Veno-occlusive disease (VOD) is an entity that presents with
thrombocytopaenia, hepatomegaly with jaundice, ascites and weight gain.
In a United Kingdom study it occurred in 1.4% of those WT patients treated
with vincristine and dactinomycin, and none of those treated with
vincristine alone 112 lending support to the belief that it is caused by
dactinomycin. It occurs shortly after chemotherapy administration and the
highest reported incidence was 8% on the SIOP-9/GPOH trial. 113 Patients
who suffer isolated thrombocytopaenia after dactinomycin administration
may be at higher risk of VOD, but it is not clear to what degree this is











dose. Treatment is supportive and fortunately there is negligible long-term
morbidity.
As with much of modern paediatric oncology, the success of WT therapy has
led investigators to focus on two areas of study. Firstly, increasing intensity
of therapy for high-risk disease in an effort to improve results, and
secondly, decreasing intensity for standard and low risk disease in order to
minimise toxicity.
Ifosfamide, carboplatin and etoposide (ICE) is an extremely
myelosuppressive regimen that is now being widely used for poor risk
relapsed WT (UFH, early relapse and extra-pulmonary relapse). Overall
survival of up to 63.6% 114 has been reported but this has still to be validated
in large trials. Other agents such as anti-angiogenesis factors, irinotecan,
oxaliplatin and histone deacetylase inhibitors are under consideration as
relapse therapies. 92 High dose chemotherapy (using such combinations as
melphalan, thiotepa, etoposide, cyclophosphamide and ifosfamide) with
autologous stem cell rescue has also been utilized but it has a low rate of
success in patients who have not already achieved complete remission with
intensive chemotherapy.
115,116 
This implies that these patients may incur
considerable additional toxicity from autologous transplant without much
added benefit.
An example of a decreased intensity regimen would be the use of vincristine











VOD. One arm of NWTS-5 made provision for the use of vincristine only for
children less than two years of age with tumours smaller than 550g. 64 This
arm was terminated early because of an increased relapse rate but all these
relapses were salvaged, and consideration is being given to repeating this
randomisation. STOP is also contemplating using vincristine only for younger
children since there seems to be no increase in the relapse rate under the
age of four years. 86
This thesis describes our experience with WT at the Red Cross Children's
Hospital (RCCH) over 25 years between 1979 and 2003.
117,118
 In analysing
this data we consider how we have measured up to the exacting standards
set by the NWTSG. Our challenge is to maximise cure and minimise toxicity.
Are there patients with low risk disease who could receive less treatment?
Can we identify patients with FH tumours who are at higher risk for relapse
and could benefit from intensified treatment? How can we improve results














The study was retrospective; the records of all patients diagnosed with WT
at RCCH between January 1979 and December 2003 were reviewed. Details
of presentation, histology and management were extracted from patient
records.
Patients were assessed at diagnosis and primary surgery was undertaken
where possible. All patients were staged radiographically with chest xray
and ultrasound abdomen and, since 1986, CT scan of the abdomen and
chest. Tumours deemed inoperable, including all BWT, were subjected to
fine needle aspiration biopsy to prove the diagnosis, and then given pre-
operative chemotherapy. The patient was then re-imaged after four to six
weeks with a view to definitive surgery. UWT were assigned a local stage of
III regardless of findings at that operation whereas BWT were staged to the
local stage of each side on imaging and/or biopsy. After surgery all patients
with unilateral stage III disease received renal bed radiotherapy, and those
with pulmonary metastases on chest xray received pulmonary radiotherapy.
Chemotherapy protocols were based on those of the NWTSG, NWTS-1
through NWTS-5. 89 RCCH WT protocols are designated 5 (denoting WT), two
digits (denoting year of inception) and 1 (denoting the number of new











which was first used in 1998. The protocol in use in 1979 was 5974, and
since that time there have been four modifications: 5811, 1891, 5921 and
5981. These protocols are set out in Appendix 2.
Duration of chemotherapy protocols changed over time, varying from 15
months initially, to 18 weeks (all stage I and FH stage II) and 24 weeks (all
other stages) currently. All patients received vincristine and dactinomycin.
Patients with stage III and IV tumours also received doxorubicin - 300 mg/m 2
until 1998, and 5 mg/kg (equivalent to 150 mg/m 2 ) since 1999. Before 1989
stages II to IV received 20 Gy renal bed irradiation. Subsequently, only those
with local stage III received renal bed radiotherapy (currently 10.8 Gy in six
fractions), and those with pulmonary metastases visible on chest xray
received pulmonary radiotherapy (currently 12 Gy in eight fractions).
Patients with pulmonary metastases visible on CT scan only were treated
with vincristine, dactinomycin and doxorubicin. Those patients whose
metastases resolved were not given pulmonary radiotherapy. The protocol
did not require biopsy of persistent lesions prior to pulmonary radiotherapy.
From the outset, all patients with UFH received vincristine, dactinomycin,
doxorubicin (300 mg/m 2 ) and cyclophosphamide. Stage I patients with UFH
were excluded from this in 1989 and now receive only vincristine and
dactinomycin. Since 1999, stage II-IV tumours with diffuse anaplastic
histology have been treated with vincristine, doxorubicin (7.5 mg/kg
equivalent to 225 mg/m 2 ), cyclophosphamide and etoposide. Stage II-IV











dactinomycin and doxorubicin (5 mg/kg equivalent to 150 mg/m 2 ). All stage
II to IV UFH tumours received renal bed radiotherapy.
Management of BWT differed in a number of respects. At the outset,
transperitoneal exploration with bilateral renal biopsies and lymph node
sampling was performed prior to commencement of chemotherapy. Since
1999 this has been replaced in some cases by percutaneous biopsy.
Vincristine, dactinomycin and doxorubicin were used in all cases. Since 1999
cyclophosphamide and etoposide have been added for diffuse anaplasia or
poorly responding tumours that are not amenable to surgery at review.
Laparotomy was usually planned two to three months after initiating
treatment with excision of tumour from the kidney with the least
involvement. If this left a viable functioning kidney the contralateral kidney
was examined and removed if extensively involved. In the last decade we
have been more surgically conservative, and if there was hope of some
salvage, another biopsy was done, the extent of the tumour marked with
titanium clips, and more chemotherapy given. Surgical exploration and
tumourectomy or partial nephrectomy was then performed two to three
months later. All attempts were made to avoid bilateral nephrectomy.
Extensive bilateral nephroblastomatosis prevented partial nephrectomy or
tumourectomy in two cases. These children were treated with three drugs
only and achieved complete remission. Both suffered local relapses which











Surgical techniques for BWT varied over the study period and changed
considerably over the last decade. Up to 1993 partial nephrectomy and
tumourectomy was done by conventional techniques with vascular pedicle
clamping for short periods of time. Since then surgical techniques have
included ice dam topical cooling of the kidney, as well as vascular control
with tumourectomy or partial nephrectomy performed under bloodless
conditions using diathermy, or more recently the ultrasonic scalpel. Two
steridrapes stuck together with a slit cut for the vascular pedicle acts as a
dam. The patient is insulated with packing swabs and after full mobilization
of the renal tumour the plastic dam is placed, the pedicle clamped and the
kidney immersed in slush ice. After a five to eight minute wait (depending
on kidney size) excision of the tumour commences. Heparin is not given.
Cross-clamp time was usually less than 30 minutes; in only one of our cases
was there evidence of any degree of acute tubular necrosis following
surgery.
On one occasion bench surgery and orthotopic autotransplantation was
required for a very extensive tumour with rhabdomyomatous change not
responding to chemotherapy. The whole kidney was removed and flushed
with EuroCollin's organ preservation solution prior to the tumour excision
and reconstruction of the pelvicalyceal system. When this was completed
the kidney was placed in the renal fossa with re-anastomosis of the vessels
and ureter. This patient has had a recurrence of tumour in the opposite
kidney away from previous resection sites within an area of biopsy-proven











term survivor despite tumour having had to be extracted from the renal
pelvis at revision surgery.
Metachronous tumours were given preoperative chemotherapy and then
tumourectomy was performed. Local renal bed radiotherapy was avoided
completely for BWT. Radiotherapy was reserved for pulmonary metastases
and local palliation.
Patients with UWT or BWT who relapsed were treated with surgery, local
and pulmonary radiotherapy (depending on site), as well as a variety of
chemotherapeutic regimens. These regimens changed over time and
included vincristine, dactinomycin, doxorubicin, cyclophosphamide,
ifosfamide, etoposide and carboplatin.
EFS and OS were estimated by the method of Kaplan and Meier. 119 EFS and
OS times were calculated in months for each patient. Cases were assigned a
censor code as follows: those who relapsed (EFS) or died of disease (OS)
were uncensored (code = 0) because their outcome was known; survivors
and patients who died of unrelated disease were censored (code = 1).
119
Survival analysis was then performed using Statistica 7.1 (Statsoft, Inc.
1984-2005). Survival curves for different subgroups were compared using the
logrank test. This is the most widely used method of comparing two or more
survival curves. 119 It is used to test the null hypothesis that there is no
difference between two or more groups in the probability of an event











for the differences between the groups offering a statistical, though not
necessarily clinical, assessment of the factor's impact. 121 We assigned a p-














208 children were diagnosed with WT during the 25-year study period.
One hundred and eighty eight had UWT. There were 77 males and 111
females representing a male:female ratio of 2:3. Age at diagnosis ranged
from 0.24 to 12.87 years. The median age at presentation was 39.2 months.
There were 24 white patients (12.8%), 85 mixed-race patients (45.2%) and
79 black patients (42%).
Of the twenty patients with BWT, 15 were synchronous (7.2% of the total)
and five metachronous (2.4% of the total). Five of the fifteen synchronous
BWT patients were male and ten female representing a male:female ratio of
1:2. Age at diagnosis ranged from 0.6 to 7.9 years. The median age was 23.9
months. There were five white patients 33.3%), three mixed-race patients
(20%) and seven black patients (46.7%).
Most presented with an abdominal mass or distension (76.9%). Abdominal
pain occurred in 52 patients (25%). There was macroscopic haematuria in 19
(9.1%) and microscopic haematuria in 44 (21.1%). Forty-two patients (20.2%)











of those with BWT (50%). Two of the UWT patients, and three of those with
BWT, presented with hypertensive cardiomyopathy.
There was only one other WT-related paraneoplastic phenomenon. This was
seen in a patient with a stage I FH WT who presented with hypertensive
cardiomyopathy. She had an elevated red cell count of 6.11 x 10 12 /1 (normal
3.9-5.1 x 10 12 /1) with a relatively normal haemoglobin of 9.4 g/dl and a low
mean corpuscular volume of 55 ft. Red cell distribution width was 27%
(normal 11.6-14.8%) and iron deficiency was confirmed by iron studies: iron
4.1 µmol/l (normal 7.1-17.9 pmol/l), total iron binding capacity 61 µmol/l
(normal 17.9-71.6 µmol/l) and saturation 6.7% (normal 20-55%). We believe
this patient had excessive erythropoietin production 122 but we were not
able to secure a pretransfusion specimen for testing. No patients presented
with hypercalcaemia or Cushing's syndrome. Routine partial thromboplastin
time (PTT) testing has been undertaken for several years. Only one child
had a prolonged PTT but was found to have normal von Willebrand factor
activity.
Weight for age was below the 3 rd centile in 41 patients (19.7%). There were
three cases of renal failure; two with elevated urea and creatinine and
normal urine output, and one with a massive tumour, raised urea and
normal creatinine, and oliguria (urine output < 0.5 ml/ kg/ hour). Two of











Thirteen patients, all with UWT, had associated abnormalities. These
included five with urogenital abnormalities, four with hemihypertrophy,
three with aniridia, and one with Beckwith-Wiedemann syndrome. There
was one instance of familial WT. A WT patient with a normal phenotype,
whose sibling had WT and renal dysplasia, was found to have a deletion of
chromosome 11. There were four patients with unrelated syndromes
(Alagille syndrome, Moebius syndrome, Chrondrodysplasia punctata and
Ectodermal dysplasia). None of the BWT patients had associated
abnormalities.
UNILATERAL WILMS' TUMOUR
Fifty-seven children were stage I (30.3%), 33 were stage II (17.6%), 60 were
stage III (31.9%) and 38 were stage IV (20.2%). Inferior vena cava tumour
thrombosis (IVCT) was present at diagnosis in 11 cases (5.9%), five with
extension into the right atrium.
Stage IV disease constituted 8.3% of the tumours among white patients,
17.6% of the tumours among mixed-race patients and 26.6% of the tumours
among black patients. Of these 38 patients with metastatic disease, 34
(89.4%) had lung metastases. Six of these 34 patients also had liver
metastases, and three others had isolated liver metastases. One had central
nervous system metastases. There were 22 patients with FH UWT who had
lung metastases. Twelve of these could be seen on chest xray, and 10 could











Characteristics of the UWT are shown in Table 1, and those of the stage IV
UWT patients are shown in Table 2.
Of the 137 tumours operable at diagnosis, 118 were weighed. Seventy-five
(63.6%) weighed more than 550g and 24 (20.3%) weighed more than one
kilogram. For purposes of comparison with NWTS-3, 79 (66.9%) had tumours
larger than 500g. Of the 28 operable stage III tumours that were weighed,
23 (82.1%) exceeded 550g and 10 (35.7%) weighed more than one kilogram.
There were 24 patients (12.8%) with UFH. Thirteen (6.9%) had diffuse
anaplasia and 11 had focal anaplasia. Only one stage I patient had UFH;  a
patient with a small focal anaplastic tumour. Fifty-four-and-a-half percent
of the patients with focal anaplasia and 23% of those with diffuse anaplasia
had stage IV disease. UFH was seen in 29.2% of white patients, 8.2% of
mixed-race patients and 12.7% of black patients. Twenty-four patients
(12.8%) had nephroblastomatosis.
Rhabdomyomatous elements were noted in the histology of 20 cases (10.6
%). Twelve of these patients underwent primary surgery and eight were
deemed inoperable and received three drug chemotherapy. Six of these
eight (75%) demonstrated a reduction in tumour volume facilitating
nephrectomy. One came to nephrectomy without a reduction in tumour
volume and one patient died of disease. There were 34 other FH tumours
that were inoperable at diagnosis. Thirty-two were evaluable for response











disease). Twenty-nine of these cases (90.6%) demonstrated a reduction in
tumour volume facilitating surgery. One came to nephrectomy without a
reduction in tumour volume and the other two died without coming to
definitive surgery.
BILATERAL WILMS' TUMOUR
Of the 15 synchronous cases, 13 presented with the tumours confined to the
kidneys (local stage I or II), one had liver metastases (stage IV) and one had
ruptured at diagnosis (stage III). On histological examination, 13 were
considered favourable (five triphasic, one mixed and seven blastemal), and
two had diffuse anaplasia. All but two had nephroblastomatosis seen on
biopsy or in the resected specimens. Rhabdomyomatous change was noted in
three of those with FH.
The five metachronous tumours presented an average of 32.8 months after
initial diagnosis (range 20 to 50 months). Three were originally stage I, and
two stage II. Histologically, one patient had focal anaplasia, three were
triphasic and one blastemal; all had nephroblastomatosis.
Characteristics of the BWT are shown in Table 3.
PATIENT OUTCOMES
One hundred and forty five patients are alive and disease free. Length of











are more than five years from diagnosis. Thirteen patients were lost to
follow up less than five years from diagnosis. All were in complete remission
following surgery and all but one had completed chemotherapy. Fifty
patients have died, 33 as a result of disease, three due to treatment-related
complications (two with anthracycline-induced cardiomyopathy and one
with chemotherapy-induced acute myeloid leukaemia), three from infection
(gastroenteritis, adenoviral pneumonia and myocarditis) and one from an
unknown cause. Ten patients were lost to follow up with active disease;
nine of them following relapse. All are presumed dead.
UNILATERAL WILMS' TUMOUR
Estimated 5-year OS for the whole group was 78.3% [figure 2]; 82.8% for FH
tumours and 47.3% for UFH tumours (p = 0.0013) [figure 3]. Estimated 5-year
EFS (representing relapse or death from any cause) for the whole group was
72.5% [figure 4]; 76.8% for FH tumours and 42.9% for UFH tumours (p =
0.0006) [figure 5].
Estimated 5-year OS for FH tumours by stage was 94.6% for stage I, 96.2% for
stage II, 78.4% for stage III, and 54.2% for stage IV (p = 0.00001) [figure 6].
The estimated 5-year EFS by stage for FH tumours was 87% for stage I, 80.6%
for stage II, 78.4% for stage III, and 50.9% for stage IV (p = 0.0016) [figure 7].
Outcomes for UWT by stage are shown in Table 1.
In the group of patients with FH stage III tumours, the estimated 5-year OS











those that were deemed inoperable (n = 20) and had pre-operative
chemotherapy (p = 0.55) [figure 8].
Three of the 11 patients with inferior vena cava tumour thrombosis (IVCT)
had primary surgery. Eight were deemed inoperable and received
chemotherapy initially. Ultimately, surgery was carried out in nine cases,
three of these on cardiopulmonary bypass. Two patients died early as a
result of thromboembolism and vascular decompensation. Six are alive and
disease free, and three died of progressive disease or following relapse.
These patients did poorly compared to the whole group; estimated 5-year
OS for the 10 FH tumours with IVCT was 60% (p = 0.035) [figure 9].
Thirteen of the 29 patients with FH stage IV tumours did poorly. Seven
patients failed to achieve remission and seven relapsed, only one of whom
survived. When stage IV FH patients were analysed in cohorts, the estimated
5-year OS for 1984-1993 was 62.9%, compared to 50% for 1994-2003 (p =
0.39) [figure 10]. FH patients with lung metastases detected on chest xray
did as well as those whose metastases were appreciated on CT scan only.
There were five survivors out of 10 in the chest xray-positive group, and six
survivors out of 12 in the CT scan only group.
Considering the small group of patients with stage I to IV UFH, those with
focal anaplasia fared as poorly as those with diffuse anaplasia; estimated 5-
year OS was 54.5% and 40.3% respectively (p = 0.47) [figure 11]. The single











Six of the 11 patients with focal anaplasia were stage IV compared to only
three of the 13 patients with diffuse anaplasia. Four of the five deaths
among those with focal anaplasia occurred in stage IV tumours.
Neither nephroblastomatosis nor rhabdomyomatous histology conferred a
poorer outcome, with estimated 5-year OS of 82.6% (p = 0.7) [figure 12] and
78.9% (p = 0.92) [figure 13] respectively. Of the 20 patients with
rhabdomyomatous histology, 40% were inoperable with a 75% response rate
to chemotherapy. This was comparable to the 90.6% response rate seen
among other FH tumours that were inoperable at diagnosis.
When the patients were analysed by race, there is a trend that does not
achieve statistical significance for white patients to do better than mixed-
race and black patients. Estimated 5-year OS was 91.3%, 81.8% and 70.6%
respectively (p = 0.08) [figure 14]. However, when metastatic disease was
excluded, there was no difference between the groups. Estimated 5-year OS
was 90.5%, 86.5% and 83.4% respectively (p = 0.79) [figure 15]. Table 2
shows that a higher proportion of black children (26.6%) had metastatic
disease compared to mixed-race (17.6%) or white children (8.3%), and that
nearly one quarter (23.8%) of black stage IV patients had UFH. Estimated 5-
year OS for black children with stage IV disease was 35.4% compared to 60%
for mixed-race children (p = 0.13) [figure 16]. Notably, when UFH tumours
were excluded from analysis, the estimated 5-year OS was still lower for
black FH stage IV patients at 47.6% compared to 61.5% for mixed-race FH











presented with stage IV disease had focal anaplasia and are alive and
disease free.
There was no difference in outcome between children treated in the second
decade and the last decade. Estimated 5-year OS and EFS was 80.3% and
73.1% for 1984-1993 and 75.1% and 70.9% for 1994-2003 (p = 0.45 and 0.96)
[figures 18 and 19].
Thirteen patients failed to achieve remission despite the use of IE
(ifosfamide and etoposide) and ICE (ifosfamide, carboplatin and etoposide)
in two of these cases respectively. Relapse occurred in 33 children of whom
20 were still receiving chemotherapy. The remaining 13 relapsed two
months to three-and-a-half years after completing therapy, only four of
them more than two years off treatment. Of the 175 patients who achieved
remission, the rate of relapse by stage was as follows: stage I 12.3%, stage II
18.2%, stage III 17.5%, stage IV 35.7%. The number of relapses by stage is
shown in Table 1. The commonest site of relapse was pulmonary, occurring
in 18 cases. There were eight local relapses, two liver relapses and five
relapses at multiple sites. Eight patients (24.2%) had UFH, and two patients
(6.1%) had nephroblastomatosis. Twelve patients received no active
treatment and one received palliative radiotherapy. The remaining twenty
were treated with chemotherapy; IE in five cases and ICE in one.
Survival was better for stage I and II patients who relapsed (eight of 13)











survivors after pulmonary relapse (five of 18) than local relapse (two
survivors out of eight). Only one of the eight patients with UFH who
relapsed survived. Five of the 13 (38.5%) who relapsed off treatment are
alive and disease free. By contrast only four of 20 (20%) who relapsed on
treatment were survivors [figure 20]. Only two of the ten patients treated
for refractory or relapsed disease with IE or ICE were survivors.
BILATERAL WILMS' TUMOUR
Of the 15 synchronous cases, seven (46.6%) are alive and disease free, six
died of disease and two patients died free of disease; one as a result of
anthracycline-induced cardiomyopathy, and one from pneumonia. While on
treatment or after completion of chemotherapy five developed metastases;
two pulmonary, two hepatic and one extensive extra-renal hilar node
involvement. All of these patients died, as did the patient who presented
with liver metastases. Four of the survivors have had local recurrences in
the kidney in areas of nephroblastomatosis away from previous resection
sites. All four underwent successful revision tumourectomy.
Three of the five metachronous cases had their original nephrectomies
elsewhere. One patient developed an isolated pulmonary metastasis seven
months after completing treatment for a stage I WT. This was removed and
four months after completing three-drug chemotherapy, she was referred to
our centre with a small tumour in an area of nephroblastomatosis in the
contralateral kidney. This was removed by tumourectomy. Three other











tumourectomy. These four patients are alive and free of disease, with
preserved renal function. The fifth patient who had also come from another
hospital presented late with an obstructive uropathy of the remaining
kidney requiring nephrostomy. He responded poorly to three-drug
chemotherapy, and was given palliative radiotherapy after an unsuccessful
attempt to remove the tumour.
Reviewing the whole group, 11 of 20 are alive free of disease - three of nine
(33%) from the first fifteen years (1979-1993), and eight of 11 (70%) from
the last decade (1994-2003). Nine have died, seven of disease and two free
of disease (anthracycline-induced cardiomyopathy and pneumonia). Six of
the seven with extra-renal spread died; the one survivor had a lung
metastasis successfully resected. All three patients with UFH are alive.
Estimated 5-year OS was 48.5% for synchronous BWT and 80% for
metachronous BWT (p = 0.3) [figure 21]. Estimated 5-year OS for
synchronous BWT improved from 34.3% in the first fifteen years (1979-1993)
to 62.5% in the last decade (1994-2003) (p = 0.42) [figure 22].
COMPLICATIONS OF TREATMENT
Complications of treatment were relatively few.
Renal function after treatment was closely monitored. One patient with











relapsed tumour and developed radiation nephritis. She does not require
dialysis. Two of the eleven surviving BWT patients have a degree of renal
i mpairment, but none have required dialysis or transplantation. Three had
isotope GFR assessment after completion of surgical intervention, and the
other eight patients had GFR calculated from serum creatinine, height and
the Schwartz constant (k=38), and these ranged from 78 to 162
ml/min/1.73m 2 . Only two of these were below 90 ml/min/1.73m 2 ; these
being 85 ml/min/1.73m 2 and 78 ml/min/1.73m 2 respectively.
One hundred and thirty one patients received anthracyclines initially or at
relapse, the cumulative dose ranging from 45 mg/m 2 to 440 mg/m 2 . Of
these, 83 received a cumulative dose over 250 mg/m 2 ; three of them
exceeding 350 mg/m 2 . Three of the 131 (2.3%) patients developed
cardiomyopathy. Of the two who died of cardiomyopathy, one received 300
mg/m 2 and the other 430 mg/m 2 as well as pulmonary radiotherapy. The
third patient received 300 mg/m 2 and is alive on antifailure treatment.
Twelve patients received ifosfamide for resistant disease or at relapse, the
cumulative dose ranging from 18 g/m 2 to 72 g/m 2 , with a mean of 38.25
g/m 2 . One patient developed nephrogenic diabetes insipidus and Fanconi's
syndrome after 36 g/m 2 and subsequently died of disease. There are only
three survivors - 65.2 to 152.6 months from diagnosis - all with normal renal











One patient developed veno-occlusive disease after dactinomycin, and one
infant suffered a brief unexplained apnoea after vincristine and
dactinomycin.
One patient developed a secondary malignancy. She was a five-year-old girl
with a stage II anaplastic UWT, who was diagnosed with secondary acute
myeloid leukaemia three-and-a-half years after completing treatment that
included doxorubicin, etoposide and renal bed radiotherapy. The leukaemia
cells had the typical translocation involving the MLL gene on the long arm of
chromosome 11 that is associated with the use of topoisomerase inhibitors
such as etoposide. The family declined further treatment and she was
palliated.
Complications of surgery occurred in 41 of 188 (21.8%) UWT patients, and
three of 20 (15%) BWT patients. There was rupture or spillage as defined by
the NWTSG (beyond the flank) in 12 UWT (6.4%), and local spillage in five
UWT, but none in the BWT. All those with NWTS-defined spillage were
treated as stage III tumours with vincristine, dactinomycin and doxorubicin
as well as renal bed irradiation (10-20 Gy). Of the 122 FH UWT that were
operable, 10 (8.2%) had NWTSG-defined spillage. In this group there were no
local relapses but two pulmonary relapses, and no difference in estimated
RFS between those with spill (80%) and those without (84.1%) (p = 0.66)
[figure 23]. Of interest is that of the five patients who experienced local
spillage - all were treated with vincristine and dactinomycin, and one











local and two pulmonary. The patient with local relapse was salvaged with
three drugs and renal bed radiotherapy.
Post-operative small bowel obstruction occurred in 20 cases (9.6%),
including two cases of volvulus, two cases of intussusception and three
closed loop obstructions. There were three episodes of wound sepsis, two
cases of wound dehiscence and one patient had major bleeding during
surgery (defined as more than 50m1/kg of blood loss). This patient was not
























Stage IV Unilateral Wilms' Tumour:





























































































































How does our cohort compare with larger reported series such as those of
NWTSG? The mild predominance of female patients is unusual, but the age
distribution is typical with a median of 39.2 months - median age of
presentation in NWTS series is 36.5 months for boys and 42.5 months for
girls. 6 Poor nutrition was a common problem. At least 20.7% of our children
were below the 3 rd centile of weight for age - the true figure may be higher
because 20.3% of the operable tumours weighed more than one kilogram.
There were 13 patients with abnormalities known to be associated with WT,
including urogenital abnormalities, hemihypertrophy, aniridia and Beckwith-
Wiedemann syndrome (BWS). This finding supports current
recommendations for WT surveillance in these patients.
123,124 
There is
consensus that children with hemihypertrophy, aniridia and BWS should be
followed with three monthly ultrasound until the age of five years, and for a











More patients had advanced disease than those on NWTSG studies; 31.9% of
our patients were stage III and 20.2% stage IV compared to 21% and 11%
respectively of NWTS-3. 62 There were also larger tumours; 66.9% of our
patients had tumours larger than 500g compared to 49% of the patients on
NWTS-3. 125 Moreover, 63.6% were more than 550g, a weight below which
tumours are associated with a good prognosis especially in children younger
than two years of age. 64 There were more anaplastic tumours (12.8%) in our
series than in NWTS-3 (3.9%).
62
NWTSG currently reports a 4-year OS for patients with FH WT that
approaches 90/0. 6 Four-year OS for stages I through IV reported by NWTS-4
was 95.6%, 91.1%, 90.9%, and 80.9% respectively. 24 Five year OS for FH WT
reported by SIOP-9 was 90%: 126 100% for stage I; 88% for stage II and 85% for
stage 111. 72 Hence our results are comparable for non-metastatic WT (OS for
FH tumours by stage was 94.6% for stage I, 96.2% for stage II, 78.4% for
stage III), but disappointing for patients with stage IV disease (OS of 54.2%).
Significantly recent stage IV patients (1994-2003) did no better than those in
earlier years (1984-1993).
What factors may be playing a role here? Historical data from NWTS-2
showed that more than half the patients with Stage IV FH WT were cured
with vincristine and dactinomycin alone. 127 Absence of pulmonary
radiotherapy from the treatment regime of the first UKCCSG WT trial
(UKW1) was implicated as the cause for the disappointing OS of 65% for











dactinomycin and doxorubicin, as well as pulmonary radiotherapy for
metastases visible on chest xray. The most likely explanation for our poor
results is that delay in diagnosis resulted in advanced presentations that
were more difficult to cure.
Favourable histology patients with CT-only lung metastases did as well as
those with chest xray metastases, despite not all receiving pulmonary
radiotherapy, and this is consistent with NWTS data. It is worth noting that
5.2% of the 2498 patients on NWTS-5 had CT-only pulmonary metastases. Of
these 129 cases, 42 were biopsied, and 11 (26.2%) were histologically
benign. 129 The authors concluded that pulmonary metastases only visible on
CT scan and not responding to first-line chemotherapy should be biopsied
before changes are made to the therapeutic regime.
In our series inoperable stage III tumours fared no better than those who
underwent nephrectomy prior to chemotherapy. This is an important check
on patient selection for surgery. Inclusion of too many patients who would
have been stage I or II at primary surgery might result in the group of
inoperable stage III tumours having better results. This would also mean that
a significant number of patients might have been over treated. Tumour size
was not an obstacle to resection with 35.7% exceeding one kilogram. The
incidence of IVCT (5.9%) was comparable to that reported by NWTSG (4%) 13°
and the third UKCCSG WT Trial (8.1%). 131 Reported OS for these patients











significant tumour shrinkage allowing definitive surgery to be performed in
most children. This was the case in our series (OS of 60%).
The results of our UFH are surprising in that focal anaplasia fared as poorly
as diffuse anaplasia. NWTS-3 and 4 reported a 4-year OS of 52.2% for stage II
to IV tumours with diffuse anaplasia. 65 The OS for a small group of children
with focal anaplasia was 100%. In our series, the larger number of stage IV
tumours among those with focal anaplasia (54.5%) probably accounts for
their poor outcome. Preliminary results of NWTS-5 suggest that two drugs
may be inadequate adjuvant treatment for stage I anaplastic tumours 134 but
we had only one stage I tumour with UFH - a patient with focal anaplasia
who is alive and disease free.
Hadley et al 78 reported poor prognosis for black patients in South Africa
with WT, and noted a high proportion of advanced local and metastatic
disease, as well as nutritional and infective co-morbidity. The same group
published a series of 67 black patients, all of whom had tumours larger than
one kilogram after neoadjuvant chemotherapy." In only 13% of these could
UFH be invoked to explain the poor response to chemotherapy. Our results
show that black patients with non-metastatic disease do as well as other
patients. Metastatic disease was seen more frequently in black patients and
conferred a very poor prognosis. In part this is explained by a higher
proportion of stage IV tumours with UFH, but even black children with FH











again, delay in diagnosis with advanced presentation is the likely
explanation.
The risk of recurrence in WT is approximately 15%.
135
 Lungs, liver,
contralateral kidney and renal bed are the commonest sites, and risk factors
include advanced stage, UFH, advanced age at diagnosis, tumour size, and
lymph node involvement. In addition, spillage or pre-operative rupture has
been demonstrated to be a risk factor for local recurrence, 136 and
nephroblastomatosis has been cited as an independent risk factor for both
relapse 137 and contralateral disease. 28 Most recurrences occur within two
years and almost all within four years. 138 In our series, UFH and high stage
were associated with increased relapse. All relapses occurred within four
years, only 12% of them beyond two years. Nephroblastomatosis occurred
more frequently in our series (12.8%) than the 4.5% reported in the
literature, 125 but did not confer additional risk of relapse. Spill or rupture
was also not associated with increased risk of local relapse.
Post-relapse survival on NWTS-2 and NWTS-3 was best for tumours of low
stage and FH, pulmonary relapse, and those relapses occurring more than 12
months after diagnosis, 139 and this was our experience. Survival is superior
in those patients not already treated with doxorubicin and radiotherapy.
136
In the literature, rhabdomyomatous change is associated with a poor
response to chemotherapy 34 but a generally favourable outcome when











rhabdomyomatous histology was comparable to that of other patients with
FH WT, as was the survival.
The rate of surgical complications was low in our series. NWTSG-defined
intra-operative spillage or rupture occurred in 8.2% of operable FH UWT;
less frequently than the 15.2% reported by NWTS-5140 but more frequently
than the 2.8% incidence reported by SIOP-9. 141 At 9.6%, the frequency of
small bowel obstruction was comparable to the 6.9% reported by NWTS-3 142
but clearly higher than the 3.7% reported by SIOP-9. 141 All other
complications were negligible.
The incidence of renal failure among survivors (0.5%) was comparable to the
0.25% reported by NWTSG for UWT. 104 Cardiomyopathy occurred in 2.3% of
our patients treated with doxorubicin, marginally higher than the 1.7%
reported by NWTS. 109 All three patients developed cardiomyopathy after
cumulative doses at or above 300mg/m 2 . The maximum dose in current use
(for anaplastic tumours) is 225mg/m 2 . There was only one second
malignancy, yielding a 0.5% incidence that is comparable with both NWTS
and STOP data.
110,111
In conclusion, NWTSG protocols employed in a South African setting with
appropriate surgical expertise, produced comparable results for non-











In a recent review of WT treatment Guilio D'Angio concluded that there is
very little to choose between primary surgery and pre-operative
chemotherapy in the face of modern, expert care. 143 He advocates early
surgery where circumstances allow, and our results show that this is possible
outside of a developed world setting.
BILATERAL WILMS' TUMOUR
Synchronous BWT comprised 7.2% of our series and metachronous BWT 2.4%,
and they presented at a younger age than those with UWT (median of 23.9
months). All but two (both synchronous BWT) had multiple nephrogenic rests
or nephroblastomatosis, and two of the synchronous BWT had diffuse
anaplasia (13.3%). This is entirely consistent with NWTSG data. Unusually,
there were no associated congenital abnormalities or syndromes.
In our series, neither UFH nor metachronous presentation was associated
with a poorer prognosis. However, when extra-renal disease developed, this
was associated with reduced survival. Multicentricity and
nephroblastomatosis was an almost universal finding, and all but two were
local stage I or II. Survival improved considerably between the first fifteen
years (34.3% for 1979-1993) and the last decade (62.5% for 1994-2003).
The prime goal in the management of patients with BWT is to provide
effective curative treatment while at the same time preserving sufficient
functioning renal tissue for normal growth and development. 144 This should











ostensibly unilateral disease, a very close look at the contralateral kidney
with biopsy of any suspicious areas. Pre-operative imaging is increasingly
accurate 145 but should not replace careful visualization of the contralateral
kidney.
146 
Any nephroblastomatosis in a resected tumour should alert the
physician to be particularly diligent in follow-up and monitoring. Where
nephroblastomatosis is identified pre- or intra-operatively, there may be a
place for nephron-sparing surgery in a selected group of infants with well-
circumscribed UWT, and the NWTSG has recommended that such an
approach should be formally studied. 28
With metachronous presentation there is only one kidney remaining and
some attempt at nephron-sparing surgery is almost always indicated. The
alternative is leaving the patient free of disease but anephric requiring
renal transplantation with all the consequences of lifelong immune
suppression and drug toxicity. With synchronous BWT, the current
recommendations for treatment are biopsy followed by neo-adjuvant
chemotherapy and then renal salvage procedures (partial nephrectomy or
tumourectomy). 9 Nephron-sparing is not advocated in the face of diffuse
anaplasia, 147 nor in cases of Denys-Drash syndrome. 15 Patients can be
considered for transplant when they have achieved two years of disease-
free survival after treatment, though this may be reduced to one year if
there is a living-related donor. 15
A number of innovations have facilitated nephron-sparing surgery. In-situ











extensive dissection and reconstruction without loss of renal function from
ischaemia. 148 In most cases the cross clamp-time is relatively short and
topical cooling with ice is sufficient. The use of the ultrasonic scalpel
facilitates dissection as it cuts so well in a wet environment, with the
residual preserved part of the kidney remaining in ice while the tumour is
resected. The Cavitron ultrasonic surgical aspirator has been used to good
effect in some centres. 148 Using loop magnification, vascular structures can
be identified and sutured and the pelvicalyceal system, if involved,
repaired. The renal artery and vein are usually large as they have supplied a
large tumour and this allows for considerable mobilization of the kidney
making surgical access and orthotopic positioning, as well as vessel
reanastomosis, easier, particularly if there was tumour shrinkage with
chemotherapy.
Bench surgery with autotransplantation 149 can be performed in exceptional
circumstances as demonstrated in one of our cases. Ex-vivo perfusion does
have the disadvantage, however, of making it very difficult to visually
discriminate between tumour, nephroblastomatosis and normal renal tissue.
Multiple frozen section biopsies may be required but can also be difficult for
the histopathologist to interpret. In-situ cold perfusion with organ
preservation solution is an alternative to bench surgery providing for longer












Tumours arising in areas of nephroblastomatosis tend to respond to
chemotherapy and this was our experience. Two patients with extensive
nephroblastomatosis achieved complete remission with chemotherapy only,
a phenomenon that has been described in a child with Beckwith-Wiedemann
syndrome.150 One patient with extensive rhabdomyomatous change had a
poor response to chemotherapy, and this phenomenon has been reported in
the literature. 35 After successful bench surgery and subsequent
contralateral tumourectomy, he suffered a recurrence of tumour, but
remains a survivor with good renal function after further nephron-sparing
surgery.
The use of radiotherapy for BWT has diminished over time; 57% of patients
on NWTS-2 and -3 8 received renal or renal-bed irradiation, compared to 42
of the 196 kidneys (21.4%) registered on the renal salvage procedure arm of
NWTS-4. 9 This supports our decision to avoid radiotherapy; its use could
come at the cost of reduced renal function and significant survival
advantage has not been demonstrated.
A particularly difficult area is that of progressive or non-responding BWT. In
NWTS-4 these tumours achieved an OS of only 66.8%. 102 Notably, only a
small percentage had anaplastic histology or rhabdomyomatous change. In
the event of a poor response to neoadjuvant chemotherapy early biopsy and
early resection is recommended, and nephron-sparing techniques may not
be feasible. Some workers have even advocated the use of brachytherapy











Other than cardiomyopathy and second malignant neoplasms, renal failure is
the commonest source of morbidity in BWT survivors. The risk of renal
failure increases with the loss of more than 50% of renal mass. 1"
Consequently, with the changing nature of treatment, the rate of renal
failure in BWT has decreased from 16.4% in NWTS-1 and -2 to 9.9% in NWTS-
3 and 3.8% in NWTS-4. 104 The absence of significant renal impairment among
our survivors is proof of the success of nephron-sparing surgery, but all
should have systematic follow-up of blood pressure, urine protein and renalfunction.144
RECOMMENDATIONS
Further advance in the management of WT depends on a number of factors.
Firstly, better risk stratification using new molecular markers 151 may
i mprove our ability to identify tumours that require more intensive therapy.
Loss of heterozygosity at chromosomes 1p and 16q has been shown to be an
adverse prognostic factor for FH WT 19 and increased telomerase expression
is associated with increased risk of relapse, 63 though not with decreased
survival. Gene expression profiling using micro array technology
152,153
appears to hold some promise in selecting out those FH tumours that are
destined to relapse. Secondly, new chemotherapeutic regimes may improve
the outcome of patients with relapsed or refractory disease. For both of
these we are largely dependant on the research efforts of the large North
American (NWTSG) and European (STOP) collaborations. Thirdly, surgical











of BWT. Tumours not responding to chemotherapy remain a challenge but
the proportion of such tumours may be smaller if nephron-sparing
techniques improve.
Success for us at RCCH will be determined by our ability to maintain current
standards of medical and surgical care, and incorporate newly proven
techniques into our treatment regimens as they become available.
Decreasing the intensity of adjuvant chemotherapy for low risk tumours
(young patients with small low stage tumours) awaits results from the latest
NWTSG trial, because we have experienced very little in the way of
treatment-related morbidity in this group. Despite the introduction of more
intensive chemotherapy regimes such as IE and ICE, we are not achieving
better results among patients with metastatic and anaplastic disease.
Future success may lie with biological therapies such as monoclonal
antibodies and small molecule enzyme inhibitors, but expense will likely
limit their availability to most of our patients. In the final analysis,
achieving better outcomes for our stage IV patients may depend as much on
improved surveillance with earlier diagnosis, as on advances in treatment
regimes.
Part of our responsibility as oncologists is to train young doctors to
recognize paediatric malignancy in the community setting and impart this
knowledge at the coalface to their nursing colleagues. In addition it behoves
us to help prepare future generations of paediatric oncologists and surgeons
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